Skip to content
Menu

Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $43

Benzinga Newsdesk 7 months ago

NewsPrice TargetAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.

Read at benzinga.com